; (bb) treatment modalities that were attempted prior to the use of the psychotropic drug; and (cc) any other information the Secretary determines appropriate; (II) the resident (or, if applicable, the resident’s designated health care agent or other surrogate under State law or regulation) provide written informed consent to the administration of the psychotropic drug; and (III) the administration of the psychotropic drug is in accordance with any plan of care that the resident has in place, including non-pharmacological interventions as appropriate that can effectively address underlying medical and environmental causes of behavioral disorders. (ii) An alternative protocol for obtaining such written informed consent— (I) in the case of emergencies; and (II) in the absence of a clearly identified designated health care agent or other surrogate under State law or regulation. (iii) Other items determined appropriate by the Secretary. (C) Timing of informed consent Under the standardized protocol, a skilled nursing facility shall obtain the written informed consent described in subparagraph (A), with respect to a psychotropic drug and a resident of the facility— (i) prior to the initial prescribing of such psychotropic drug to such resident if such resident does not have a current prescription for such psychotropic drug at the time such resident is admitted to the facility